Pharma BD Deal Intelligence
A $5.1 billion collaboration expansion that gave Gilead option rights across Galapagos's entire pipeline, including filgotinib (Jyseleca), while Galapagos gained 50:50 cost-sharing and greater control over European commercialization strategy.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead deepens Galapagos ties with $5.1 billion deal, including $3.95 billion upfront and $1.1 billion equity investment to raise its stake to 22%.
Gilead and Galapagos enter a transformative 10-year, $5.1 billion R&D collaboration, with Gilead investing $3.95 billion in equity and paying $1.1 billion in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Gilead invested $5.1 billion to deepen its collaboration with Galapagos, comprising a $3.95 billion upfront payment and a $1.1 billion equity investment (raising its stake from 12.3% to 22%). The 10-year agreement gave Gilead access to six clinical-phase assets, 20 preclinical programs, and option rights on all future Galapagos pipeline programs. For filgotinib specifically, Galapagos gained greater involvement in global strategy and European commercialization, with costs shared 50:50 (replacing the prior 80:20 split).
70K US cases/yr · $25.0B Global IBD Therapeutics Market (2024)
IBD (ulcerative colitis and Crohn's disease) affects ~3 million Americans. JAK inhibitors have gained traction in UC (tofacitinib, upadacitinib). Filgotinib's IBD program showed mixed results with the UC trial showing modest efficacy and Crohn's development discontinued.
IBD market leaders: Humira (biosimilars), Stelara (biosimilar coming), Entyvio (Takeda), Skyrizi (AbbVie, growing rapidly), Rinvoq (AbbVie). JAK inhibitors face FDA black box warnings. Filgotinib underperformed vs. upadacitinib in UC. The IBD market is highly competitive with $25B+ globally.
50K US cases/yr · $4.0B Global IPF Market (2024)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease of unknown cause, characterized histologically and radiographically by usual interstitial pneumonia (UIP). It occurs predominantly in adults over 60 and is more common in men and in former smokers. U.S. prevalence estimates range from roughly 100,000 to 150,000 cases, with incidence rising with age. Patients typically present with gradually worsening exertional dyspnea and a dry cough, bibasilar inspiratory crackles, and sometimes digital clubbing. High-resolution CT showing a UIP pattern (subpleural, basal-predominant reticulation with honeycombing and traction bronchiectasis) is central to diagnosis; surgical or transbronchial lung biopsy is used when imaging is indeterminate. Prognosis is poor, with historical median survival of 3-5 years from diagnosis, though course is variable and includes acute exacerbations associated with high mortality. Management includes antifibrotic therapy, supplemental oxygen, pulmonary rehabilitation, treatment of comorbidities (GERD, pulmonary hypertension), and lung transplantation evaluation in eligible patients.
GLPG1690's failure was another blow to the Gilead-Galapagos deal. The autotaxin/LPA pathway remains a target of interest but this specific molecule failed. Competing IPF programs: BI (nerandomilast, positive Phase III), Roche (various), FibroGen. The IPF market has significant unmet need with only two slowing but not halting disease.
$28.0B 7 Major Markets RA (2024)
Rheumatoid arthritis affects ~1.3-1.5 million Americans. The Gilead-Galapagos deal ($5.1B) centered on filgotinib (Jyseleca), a selective JAK1 inhibitor. FDA rejected the US application in 2020 over fertility/spermatogenesis concerns, a major setback that limited the deal's value.
Filgotinib's US rejection was devastating to the deal thesis. Jyseleca is approved in EU but generates only ~$150M. Competitors (Rinvoq by AbbVie, Xeljanz by Pfizer, Olumiant by Lilly) dominate the JAK class. Gilead subsequently wrote down $3.5B+ of the deal value. The broader Galapagos pipeline also disappointed.
Gilead Sciences Inc. completed its acquisition of Galapagos NV for $5.1B. Gilead invested $5.1 billion to deepen its collaboration with Galapagos, comprising a $3.95 billion upfront payment and a $1.1 billion equity investment (raising its stake from 12.3% to 22%).
Complete Response Letter cited safety concerns. No viable US approval path. Regulatory step in Gilead Sciences Inc.'s acquisition process for Galapagos NV.
European Commission approved filgotinib, limited commercial opportunity. Regulatory step in Gilead Sciences Inc.'s acquisition process for Galapagos NV.
Gilead paid EUR160M amendment fee. Abandoned US RA path. Part of Gilead Sciences Inc.'s $5.1B deal to acquire Galapagos NV.
Minimal commercial uptake in Europe despite approval. Reflects financial performance following Gilead Sciences Inc.'s $5.1B acquisition of Galapagos NV.
Gilead relinquished its ex-EU option rights on Galapagos pipeline in Jan 2024, ending the restructured 2019 partnership early. $5.1B upfront largely written down after filgotinib failure.
See timeline for full assessment. Assessment of Gilead Sciences Inc.'s $5.1B acquisition of Galapagos NV and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Galapagos NV (this deal) | 2019 | $5.1B | 25 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2019 deals · Gilead Sciences Inc. deals · Gastroenterology deals